Skip to main content
Fig. 1 | Trials

Fig. 1

From: Efficacy of selenium supplementation for mild-to-moderate Graves’ ophthalmopathy in a selenium-sufficient area (SeGOSS trial): study protocol for a phase III, multicenter, open-label, randomized, controlled intervention trial

Fig. 1

Schematic description of the study design. After screening, the enrolled patients will be randomized to receive either vitamin B complex only (control group) or vitamin B complex + selenium (selenium group) for 6 months. Assessments including the quality of life and clinical activity of GO evaluation, thyroid function testing, and thyroid autoantibody titers will be performed at 3 and 6 months

Back to article page

Trials

ISSN: 1745-6215